Lbp Am Sa Boosts Holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

LBP AM SA lifted its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 20.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 305,221 shares of the company's stock after buying an additional 52,303 shares during the period. LBP AM SA owned about 0.13% of BioNTech worth $27,793,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its holdings in BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after buying an additional 246 shares during the period. Allianz SE acquired a new position in BioNTech in the 4th quarter worth $90,000. Goodman Advisory Group LLC acquired a new stake in shares of BioNTech in the 1st quarter valued at about $105,000. Tower Research Capital LLC TRC boosted its position in shares of BioNTech by 61.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,881 shares of the company's stock worth $214,000 after buying an additional 713 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in BioNTech by 7.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after buying an additional 128 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on BNTX. Morgan Stanley set a $133.00 price objective on shares of BioNTech and gave the stock an "overweight" rating in a research report on Thursday. JPMorgan Chase & Co. reduced their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a research report on Thursday, May 22nd. HC Wainwright reissued a "buy" rating and issued a $138.00 price objective on shares of BioNTech in a research report on Wednesday, June 25th. The Goldman Sachs Group started coverage on BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 target price for the company. Finally, Truist Financial reaffirmed a "buy" rating and set a $155.00 price objective (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $137.91.

BioNTech Trading Up 0.2%

NASDAQ BNTX traded up $0.18 during mid-day trading on Thursday, reaching $111.96. 247,865 shares of the stock were exchanged, compared to its average volume of 987,495. The stock has a 50 day simple moving average of $103.17 and a 200-day simple moving average of $106.86. BioNTech SE Sponsored ADR has a one year low of $76.53 and a one year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. The stock has a market cap of $26.91 billion, a P/E ratio of -32.93 and a beta of 1.29.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.